InDex Pharmaceuticals Holding AB (publ), a Sweden-based pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options, announced on Friday an update in the timing of the dose selection in the ongoing phase III study CONCLUDE with the drug candidate cobitolimod.

The result of the dose selection is likely to be provided in the fourth quarter of 2023. The company will have finalised the evaluation of consequences on the overall development timeline, including top line results in CONCLUDE, at that point in time.

The CONCLUDE study, a phase III study, is assessing the first-in-class TLR9 agonist cobitolimod as a novel treatment for subjects with moderate to severe left-sided ulcerative colitis. It includes around 440 subjects and is being carried out at various clinics in more than 30 countries in Europe, the Americas and the Asia-Pacific region.